They need funding to continue progressing. From th
Post# of 36566
(Total Views: 224)
Posted On: 11/16/2019 4:08:27 PM
They need funding to continue progressing. From their website:
INVESTMENT HIGHLIGHTS
Large target market opportunities in the diagnosis and treatment of diabetes
· Highly differentiated intellectual property base protected by a series of directly-owned (3) global patents
· Exceptional team of scientists as directors of research with established reputations in the fields of endocrinology, diabetes, clinical trials and biomedical engineering; widely recognized in the diabetes space
· History of collaboration with influential leaders in the diabetes research and cell technology fields, as evidenced in research contacts and investigative collaborations with major universities
· Promising data from a series of animal studies and human subjects administered transplant with a 5 year follow-up, validating the safety and efficacy of our treatment and the microencapsulation method
· Our patented technologies have broad applications; we are interested in exploring strategic partnerships that bring incremental expertise, resources, geographic reach and disease area knowledge to our platform
· Altucell sees high value in forming select, strategic collaborations
* Strategic Investor is Sterling Pharmaceuticals of Italy (http://www.sterling.it/), a specialty pharmaceutical products manufacturer.
Financial Plan
To date most of the development has been funded by the CEO & founder. The company’s results and strategic positioning based on sound science with a remarkable technical/medical team are now well positioned to make Altucell a highly attractive corporate partner with enormous licensing income potential across numerous diseases.
The Company is now seeking funding for:
· Research & Development for the next 18 months on the 3 diseases outlined in the Road Map
· Preparation of IND materials for submission to AIFA (Italian Reg. Agency)
· The head of the FDA for cell division is requesting that our Italian documents be submitted for a pre IND meeting with the FDA, to define the remaining requirements for clinical trials
· Corporate SG&A expenses
INVESTMENT HIGHLIGHTS
Large target market opportunities in the diagnosis and treatment of diabetes
· Highly differentiated intellectual property base protected by a series of directly-owned (3) global patents
· Exceptional team of scientists as directors of research with established reputations in the fields of endocrinology, diabetes, clinical trials and biomedical engineering; widely recognized in the diabetes space
· History of collaboration with influential leaders in the diabetes research and cell technology fields, as evidenced in research contacts and investigative collaborations with major universities
· Promising data from a series of animal studies and human subjects administered transplant with a 5 year follow-up, validating the safety and efficacy of our treatment and the microencapsulation method
· Our patented technologies have broad applications; we are interested in exploring strategic partnerships that bring incremental expertise, resources, geographic reach and disease area knowledge to our platform
· Altucell sees high value in forming select, strategic collaborations
* Strategic Investor is Sterling Pharmaceuticals of Italy (http://www.sterling.it/), a specialty pharmaceutical products manufacturer.
Financial Plan
To date most of the development has been funded by the CEO & founder. The company’s results and strategic positioning based on sound science with a remarkable technical/medical team are now well positioned to make Altucell a highly attractive corporate partner with enormous licensing income potential across numerous diseases.
The Company is now seeking funding for:
· Research & Development for the next 18 months on the 3 diseases outlined in the Road Map
· Preparation of IND materials for submission to AIFA (Italian Reg. Agency)
· The head of the FDA for cell division is requesting that our Italian documents be submitted for a pre IND meeting with the FDA, to define the remaining requirements for clinical trials
· Corporate SG&A expenses
(1)
(0)